Gilead Makes Cell Therapy The Base Of Its Oncology Platform With Kite Buy

Gilead's Kite acquisition may finally have appeased investors' thirst for a major deal with a transaction that will diversify revenue and expand its oncology portfolio.

Handshake of businessmen

Gilead Sciences Inc.'s $11.9bn acquisition of chimeric antigen receptor T cell (CAR-T) therapy developer Kite Pharma Inc. will make cell therapy the foundation of the company's oncology platform as it diversifies its revenue base beyond small molecule antiviral medicines.

Gilead executives said in a same-day call about the transaction announced on Aug. 28 that the company will build its oncology business around cell therapies with an eye on improving Kite's products and developing combination regimens that incorporate CAR-T and T-cell receptor (TCR) therapies

For more on what Gilead sees of value in Kite and its pipeline, read:

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By 

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

 

The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.